Ionis Pharmaceuticals, Inc.

The FDA approval of our breakthrough treatment – the first and only medicine in the U.S. for adults with familial chylomicronemia syndrome (FCS), as an adjunct to diet – is an important milestone for this rare disease community. Watch this video from our CEO, Brett P. Monia, PhD, to learn more about the significance of this approval.

Ionis will host an investor webcast to discuss the U.S. FDA approval of our medicine for the treatment of adults with familial chylomicronemia syndrome (FCS), as an adjunct to diet. Read more and access a link to the webcast here: https://lnkd.in/evZuFmBW

BREAKING NEWS: We’re thrilled to share we have received U.S. FDA approval for TRYNGOLZA™ (olezarsen), cementing Ionis as a fully integrated commercial-stage biotech company. Read more: https://lnkd.in/eg2G4NpH

Holiday travel can be stressful under any circumstance, but particularly if you’re living with a chronic disease like hereditary angioedema (#HAE), a rare and life-threatening genetic condition that involves recurrent attacks of severe swelling in various parts of the body, which can cause severe pain and significantly disrupt daily life. If you’re traveling this season, remember to plan ahead for a safe and successful trip. Check out the resources available from the Hereditary Angioedema Association - HAEA for helpful tips and tricks: https://lnkd.in/g-gEXR6d

This holiday season, we’re proud of our Ions who teamed up in a big way to live our values and make a real impact for communities where we live and work! More than 100 employees took part in our fifth annual Holiday Hope, participating virtually and across our Carlsbad, Boston and Dublin offices for a day of volunteering, giving back while growing our understanding and empathy. Together we supported nine non-profit partners, assembling 275 gift packages for ALS communities, 200 hygiene kits for patients and unhoused families and more than 1,000 STEM education kits, among other acts of service. Ions in our Carlsbad office learned about improv as an adaptive experience for people living with neurological diseases and took part in an immersive workshop to experience what it’s like completing daily tasks with dementia.  

HCPs: KnowYourTGs.com is a patient resource offering comprehensive information about familial chylomicronemia syndrome (FCS). If you have patients #livingwithFCS, this site contains educational and supportive materials that may be able to help them better manage FCS. 

Familial chylomicronemia syndrome (FCS) is a genetic, #raredisease that can be difficult to diagnose. If you suspect you may be #livingwithFCS, this signs & symptoms quiz can help: https://lnkd.in/e8A9anyr

With one week until RNA at the Bench and Bedside IV, we’re looking forward to forging new collaborations and engaging in innovative dialogue that will advance the scientific community’s understanding and pursuit of nucleic acid medicines. On Monday, 12/9, Ionis’ Ian Huggins, a Research Fellow in the Medicinal Chemistry Group, will present on ligand mediated delivery of oligonucleotides across the blood brain barrier. On Tuesday, 12/10, Executive Director of Clinical Development for Ionis, Becky Crean, PhD, will share insights on the antisense oligonucleotide approach to developing a therapeutic for Angelman Syndrome. Thank you to our co-organizers, Alnylam Pharmaceuticals, Nature Biotechnology, and UC San Diego School of Medicine. Explore all sessions and learn more about the conference: https://lnkd.in/eu89e9uJ

November is #NationalFamilyCaregiversMonth. Many conditions place tremendous burden not only on people living with the disease, but also on the family members who love and help care for them. We honor caregivers in our community and beyond who work tirelessly to improve lives and demonstrate radical empathy that inspires us all. Learn more and discover resources for caregivers: https://lnkd.in/e2MnMEpg

November 17th is #InternationalERGDay, an opportunity to celebrate the employee resource groups that make our organization a stronger, more inclusive and more connected place to work. Last week, we held our annual ERG Summit, gathering more than 250 Ions to learn about our ERGs, participate in Q&As and share firsthand experiences of the benefits of joining one of our nine groups. We finished a great day of educating and recruiting new members with a learning opportunity to make our ERGs even more impactful in the year to come. Learn more about our diversity, equity and inclusion purpose: https://lnkd.in/e_UggfRn